<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Aim.</bold> The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature.Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis.<bold>Methods.</bold> Descriptive, statistical, retrospective.<bold>Results and Conclusion</bold>. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).</abstract>

Aim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature.Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis.Methods. Descriptive, statistical, retrospective.Results and Conclusion. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).

Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

National Pirogov Memorial Medical University

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Aim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on...

Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

Publié en ligne: 25 juin 2020

Pages: 57 - 60

Reçu: 11 avr. 2019

Accepté: 27 juil. 2019

DOI: https://doi.org/10.2478/cipms-2020-0011

Mots clés
antidepressant, peptic ulcer, proton pump inhibitors, efficiency

© 2020 Olesya P. Balitska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

Publié en ligne: 25 juin 2020

Pages: 57 - 60

Reçu: 11 avr. 2019

Accepté: 27 juil. 2019

DOI: https://doi.org/10.2478/cipms-2020-0011

Mots clésantidepressant, peptic ulcer, proton pump inhibitors, efficiency

© 2020 Olesya P. Balitska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
antidepressant, peptic ulcer, proton pump inhibitors, efficiency